EUVIMEDEUVIMED entdecken
Open Access · CC0

Dual inhibition of oxidative phosphorylation and glycolysis exerts a synergistic antitumor effect on colorectal and gastric cancer by creating energy depletion and preventing metabolic switch

Yuki Aisu iD, Nobu Oshima iD, Fuminori Hyodo, Abdelazim Elsayed Elhelaly, Akihiko Masuo, Tomoaki Okada, Shigeo Hisamori, Shigeru Tsunoda, Koya Hida, Tomonori Morimoto iD, Hiroyuki Miyoshi, Makoto M Taketo und 4 weitere

PLOS ONE · 12.12.2024 · 19 (12) · e0309700

DOI: 10.1371/journal.pone.0309700 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 12.12.2024. Verfasst von Yuki Aisu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan. Hauptthemen laut MEDLINE: Oxidative Phosphorylation, Glycolysis, Stomach Neoplasms, Colorectal Neoplasms. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: Japan Society for the Promotion of Science, Japan Science and Technology Agency, Center for One Medicine Innovative Translational Research Gifu 458 University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pyruvate is situated at the intersection of oxidative phosphorylation (OXPHOS) and glycolysis, which are the primary energy-producing pathways in cells. Cancer therapies targeting these pathways have been previously documented, indicating that inhibiting one pathway may lead to functional compensation by the other, resulting in an insufficient antitumor effect. Thus, effective cancer treatment necessitates concurrent and comprehensive suppression of both. However, whether a metabolic switch between the metabolic pathways occurs in colorectal and gastric cancer cells and whether blocking it by inhibiting both pathways has an antitumor effect remain to be determined. In the present study, we used two small molecules, namely OXPHOS and glycolysis inhibitors, to target pyruvate metabolic pathways as a cancer treatment in these cancer cells. OXPHOS and glycolysis inhibition each augmented the other metabolic pathway in vitro and in vivo . OXPHOS inhibition alone enhanced glycolysis and showed antitumor effects on colorectal and gastric cancer cells in vitro and in vivo . Moreover, glycolysis inhibition in addition to OXPHOS inhibition blocked the metabolic switch from OXPHOS to glycolysis, causing an energy depletion and deterioration of the tumor microenvironment that synergistically enhanced the antitumor effect of OXPHOS inhibitors. In addition, using hyperpolarized 13 C-magnetic resonance spectroscopic imaging (HP-MRSI), which enables real-time and in vivo monitoring of molecules containing 13 C, we visualized how the inhibitors shifted the flux of pyruvate and how this dual inhibition in colorectal and gastric cancer mouse models altered the two pathways. Integrating dual inhibition of OXPHOS and glycolysis with HP-MRSI, this therapeutic model shows promise as a future "cancer theranostics" treatment option.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oxidative PhosphorylationGlycolysisStomach NeoplasmsColorectal NeoplasmsHumansAnimalsMiceCell Line, TumorEnergy MetabolismAntineoplastic AgentsXenograft Model Antitumor AssaysMice, NudePyruvic AcidTumor Microenvironment

Substanzen

Antineoplastic AgentsPyruvic Acid

Autor:innen und Institutionen

  • Department of Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Department of Surgery, Kobe City Medical Center General Hospital, Kobe, Japan.
  • Department of Radiology, Gifu University Hospital, Gifu, Japan.
  • Department of Radiology, Frontier Science for Imaging, Gifu University, Gifu, Japan.
  • Colon Cancer Project, Kyoto University Hospital-iACT, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • National Cancer Institute, Urologic Oncology Branch, Center for Cancer Research, NIH, Bethesda, Maryland, United States of America.

ORCID-Profile: Yuki Aisu, Nobu Oshima, Tomonori Morimoto

Förderung

  • Japan Society for the Promotion of Science
  • Japan Science and Technology Agency
  • Center for One Medicine Innovative Translational Research Gifu 458 University

Zitieren

APA

Aisu, Y., Oshima, N., Hyodo, F., Elhelaly, A. E., Masuo, A., Okada, T., Hisamori, S., Tsunoda, S., Hida, K., Morimoto, T., Miyoshi, H., Taketo, M. M., Matsuo, M., Neckers, L. M., Sakai, Y., & Obama, K. (2024). Dual inhibition of oxidative phosphorylation and glycolysis exerts a synergistic antitumor effect on colorectal and gastric cancer by creating energy depletion and preventing metabolic switch. PLOS ONE, 19(12), e0309700. https://doi.org/10.1371/journal.pone.0309700

Vancouver

Aisu Y, Oshima N, Hyodo F, Elhelaly AE, Masuo A, Okada T, et al. Dual inhibition of oxidative phosphorylation and glycolysis exerts a synergistic antitumor effect on colorectal and gastric cancer by creating energy depletion and preventing metabolic switch. PLOS ONE. 2024;19(12):e0309700. doi:10.1371/journal.pone.0309700

BibTeX
@article{Aisu2024,
  author = {Aisu, Yuki and Oshima, Nobu and Hyodo, Fuminori and Elhelaly, Abdelazim Elsayed and Masuo, Akihiko and Okada, Tomoaki and Hisamori, Shigeo and Tsunoda, Shigeru and Hida, Koya and Morimoto, Tomonori and Miyoshi, Hiroyuki and Taketo, Makoto M and Matsuo, Masayuki and Neckers, Leonard M and Sakai, Yoshiharu and Obama, Kazutaka},
  title = {Dual inhibition of oxidative phosphorylation and glycolysis exerts a synergistic antitumor effect on colorectal and gastric cancer by creating energy depletion and preventing metabolic switch},
  journal = {PLOS ONE},
  year = {2024},
  volume = {19},
  number = {12},
  pages = {e0309700},
  doi = {10.1371/journal.pone.0309700}
}
Kostenlos starten →